Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6274716 | 0.94 | HTR6 (0.37) | HTR6 | |
| SCHEMBL946511 | 0.94 | HTR6 (0.39) | HTR6 | |
| SCHEMBL4453791 | 0.92 | HTR6 (0.38) | HTR6SMN1; SMN2 | |
| SCHEMBL6487010 | 0.88 | HTR6 (0.34) | HTR6 | |
| SCHEMBL2010172 | 0.84 | HTR6 (0.35) | HTR6HPGDKMT2ASMN1; SMN2 | |
| SCHEMBL2778573 | 0.84 | — | — | |
| SCHEMBL2241191 | 0.81 | — | — | |
| SCHEMBL236881 | 0.81 | CYP2D6 (0.30) | KMT2A | |
| SCHEMBL731008 | 0.79 | — | — | |
| SCHEMBL871079 | 0.79 | HTR6 (0.38) | HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3212641-B1 | THIAZOLES AS MODULATORS OF RORYT | JANSSEN PHARMACEUTICA NV (BE) | 2018-12-05 | — | — | EP | claimed |
| EP-3212641-A1 | THIAZOLES AS MODULATORS OF RORyt | Janssen Pharmaceutica NV (BE) | 2017-09-06 | — | — | EP | claimed |
| WO-2016069976-A1 | THIAZOLES AS MODULATORS OF RORyt | JANSSEN PHARMACEUTICA NV (BE) | 2016-05-06 | — | — | WO | claimed |
| US-20160120850-A1 | THIAZOLES AS MODULATORS OF RORyt | JANSSEN PHARMACEUTICA NV (US) | 2016-05-05 | — | — | US | claimed |
| US-6855730-B2 | 3-methylidenyl-2-indolinone modulators of protein kinase | SUGEN, INC. (US) | 2005-02-15 | — | — | US | claimed |
| US-20040024010-A1 | 3-methylidenyl-2-indolinone modulators of protein kinase | SUGEN, INC. | 2004-02-05 | — | — | US | claimed |
| EP-1042322-B1 | Kv2.1 ANTAGONISTS | GLAXO GROUP LTD (GB) | 2002-04-17 | — | — | EP | claimed |
| JP-3255930-B2 | — | — | 2002-02-12 | — | — | JP | claimed |
| US-6294580-B1 | FOR THERAPY AND PROPHYLAXIS OF TYPE II OR NON-INSULIN DEPENDENT DIABETES MELLITUS, HYPERGLYCAEMIA, DYSLIPIDEMIA, TYPE II DIABETES, TYPE I DIABETES, HYPERTRIGLYCERIDEMIA, SYNDROME X, INSULIN RESISTANCE, HEART FAILURE | GLAXO WELLCOME INC. | 2001-09-25 | — | — | US | claimed |
| EP-0888317-B1 | SUBSTITUTED 4-HYDROXY-PHENYLALCANOIC ACID DERIVATIVES WITH AGONIST ACTIVITY TO PPAR-GAMMA | GLAXO GROUP LTD (GB) | 2001-09-12 | — | — | EP | claimed |
| WO-2000008202-A9 | 3-METHYLIDENYL-2-INDOLINONE MODULATORS OF PROTEIN KINASE | SUGEN INC (US) | 2000-07-27 | — | — | WO | claimed |
| JP-2000507216-A | — | — | 2000-06-13 | — | — | JP | claimed |
| WO-2000008202-A2 | 3-METHYLIDENYL-2-INDOLINONE MODULATORS OF PROTEIN KINASE | SUGEN, INC. (US) | 2000-02-17 | — | — | WO | claimed |
| EP-0888317-A1 | SUBSTITUTED 4-HYDROXY-PHENYLALCANOIC ACID DERIVATIVES WITH AGONIST ACTIVITY TO PPAR-GAMMA | GLAXO GROUP LIMITED (GB) | 1999-01-07 | — | — | EP | claimed |
| WO-1997031907-A1 | SUBSTITUTED 4-HYDROXY-PHENYLALCANOIC ACID DERIVATIVES WITH AGONIST ACTIVITY TO PPAR-GAMMA | GLAXO GROUP LIMITED (GB) | 1997-09-04 | — | — | WO | claimed |
| EP-0153580-B2 | NAPHTHYRIDINE ANTIBACTERIAL COMPOUNDS | ABBOTT LABORATORIES (US) | 1993-03-17 | — | — | EP | claimed |
| EP-3212641-B1 | THIAZOLES AS MODULATORS OF RORYT | JANSSEN PHARMACEUTICA NV (BE) | 2018-12-05 | — | — | EP | disclosed |
| US-10080744-B2 | Thiazoles as modulators of RORγt | JANSSEN PHARMACEUTICA NV (BE) | 2018-09-25 | — | — | US | disclosed |
| WO-1997043287-A1 | CARBOLINE DERIVATIVES | ICOS CORPORATION (US) | 1997-11-20 | — | — | WO | disclosed |
| WO-1997031907-A1 | SUBSTITUTED 4-HYDROXY-PHENYLALCANOIC ACID DERIVATIVES WITH AGONIST ACTIVITY TO PPAR-GAMMA | GLAXO GROUP LIMITED (GB) | 1997-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160120850-A1 | THIAZOLES AS MODULATORS OF RORyt | RORC, RORB, RORA | HTR6 1844/4885HRH1 153/4885HPGD 3890/4885 |
| US-10080744-B2 | Thiazoles as modulators of RORγt | RORB, RORA, RORC | HTR6 2896/4885HRH1 417/4885HPGD 2998/4885 |
| US-20040024010-A1 | 3-methylidenyl-2-indolinone modulators of protein kinase | DMPK, MAP4K3, MAP3K20 | HTR6 1286/4885HRH1 3961/4885HPGD 674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.